Search clinical trials for: Custirsen

Total 12 results

Achieve Life Sciences
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Cardiac Conduction and Repolarization

United States
Achieve Life Sciences

Completed

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Prostate Cancer

Canada
Achieve Life Sciences

Completed

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Canada
NCIC Clinical Trials Group

Completed

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

Canada
NCIC Clinical Trials Group

Completed

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Kidney Cancer | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer
Achieve Life Sciences

Unknown

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Taiwan, Spain, Israel, Italy, Korea, Republic of, New Zealand, Australia, Germany, United States, Hungary, Poland, Russian Federation, Singapore, Thailand, Ukraine
Achieve Life Sciences
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

Cancer

United States
Achieve Life Sciences

Completed

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)

Prostate Cancer

France, United States, Canada, Australia, Hungary, Czech Republic, Russian Federation, United Kingdom
NCIC Clinical Trials Group

Completed

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Prostate Cancer

United States, Canada
NCIC Clinical Trials Group

Completed

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Prostate Cancer

Canada
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada
Achieve Life Sciences
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)

Prostate Cancer

United States, Belgium, Canada, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom

Search clinical trials for: Custirsen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations